Loxo signs lucrative cancer drug deal with Bayer, but shares fall

(Reuters) – Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany’s Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.


Source: Reuters Health News